ClinicalTrials.gg
Active, not recruitingNCT07406191Updated May 14, 2026

WB-EMS Effects on Cardiometabolic Risk Factors

An interventional study of WB-EMS and Control in Hypertension, Metabolic Syndrome and Hypercholesterolemia, sponsored by University of Erlangen-Nürnberg Medical School. Active, not recruiting at 2 sites in Germany. Open to male participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School — 2 open to participants now, 3 under way, none of them phase 3. Hypertension · University of Erlangen-Nürnberg Medical School.

Enrollment
6th of 11
28 · median 28
Started
2026
the only one that year
No phase
6 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 14th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 50 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, or all of them as a file.
02

Study summary

From the age of 50 onwards, there is a disproportionate decline in muscle strength, mass and function, which can be prevented or at least delayed by physical training. Unfortunately, many training programmes are very time-consuming and strenuous and are therefore not carried out consistently. Whole-body electromyostimulation (WB-EMS), a technology in which all major muscle groups are stimulated with an adjusted stimulation level, could be a time-effective and joint-friendly alternative.

However, there are some contraindications to the widespread use of this technology, which are particularly common in middle-aged and elderly people. For example, high blood pressure, which affects more than half of men over the age of 50 in Germany, is considered a contraindication for WB-EMS training. However, this assessment is not very reliable; at least, acute WB-EMS application does not lead to an increase in blood pressure. In addition, there are no study results available for long-term WB-EMS application in people with high blood pressure.

The present study particularly investigate whether and to what extent several weeks of WB-EMS training has an effect on resting blood pressure in people with mild blood pressure. Additionally, the effect of WB-EMS on other cardiometabolic risk factors and physical function will be addressed.

03

Conditions studied

  • Hypertension
  • Metabolic Syndrome
  • Hypercholesterolemia
  • Hypertriglyceridemia
  • Overweight and Obesity
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Grade 1 hypertension: systolic 140 and/or diastolic 90 mmHg
  • overweight or obese ( > 25 kg/m2)

Exclusion criteria

Exclusion Criteria:

  • blood pressure-lowering pharmacologic therapy.
  • WB-EMS application and regular resistance exercise training
  • Conditions and illnesses that preclude intensive physical exertion
  • Severe cardiac arrhythmia
  • Heart failure
  • acute pulmonary embolism
  • acute myocarditis
  • severe hypertension, e.g. blood pressure > 200 mmHg systolic and/or >110 mmHg diastolic
  • for bioimpedance analysis (e.g. pacemaker)
  • Contraindications for WB-EMS application (e.g. acute infections/fever, epilepsy)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Whole-body electromyostimulation

    12 weeks of Whole-body electromyostimulation, 1.5x 20min/week

    Other: WB-EMS

  • Other
    Control group

    12 weeks without additional intervention.

    Other: Control

Interventions

  • OtherWB-EMS

    12 weeks of WB-EMS, 1.5x20 min/week

    Also known as: Electromyostimulation

  • OtherControl

    12 weeks without additional intervention and without life style changes

    Also known as: Non-intervention control group

06

What researchers measure

Primary outcomes

  1. Resting blood pressure

    Changes of mean arterial blood pressure after 10 min of rest in a sitting position as assessed by an automatic sphygmomanometer

    Time frame: At baseline and after 12 weeks of intervention

  2. Metabolic syndrome

    Changes of the Metabolic Syndrome (MetS) as determined by the MetS-Z-Score

    Time frame: At baseline and after 12 weeks of intervention

Secondary outcomes

  1. Body fat rate

    Changes of body fat rate as determined by Bio Impedance Analysis (BIA)

    Time frame: At baseline and after 12 weeks of intervention

  2. Lean body mass

    Changes of lean body mass as determined by Bio Impedance Analysis (BIA)

    Time frame: At baseline and after 12 weeks of intervention

  3. Maximum muscle strength

    Changes of maximum hip-/leg extension strength as determined by a leg press

    Time frame: At baseline and after 12weeks of intervention

  4. Aerobic capacity

    Changes of aerobic capacity as determined by a stepwise crosstrainer test to submaximum exertion

    Time frame: At baseline and after 12 weeks of intervention

  5. Lower extremity muscle power

    Changes of lower extremity muscle power as determined by a 5times sit to stand test

    Time frame: At baseline and after 12 weeks of intervention

  6. Concentration of inflammatory markers

    Changes of inflammatory markers as determined by cytokines

    Time frame: At baseline and after 12 weeks of intervention

  7. Concentration of adipose-tissue derived hormones

    Changes of adipose tissue-derived hormones as determined by adipokines

    Time frame: At baseline and after 12 weeks of intervention

  8. Concentration of muscle-tissue derived hormones

    Changes of muscle-tissue derived hormones as determined by myokines

    Time frame: At baseline and after 12 weeks of intervention

  9. Bluthochdruck - Fragebogen zur Lebenszufriedenheit [Hypertension - Quality of Life Questionnaire]

    Changes in QoL in people with hypertension according to a questionnaire from 1 (excellent, completely agree) to 6 (very bad/completely disagree). Lower scores indicate better outcomes

    Time frame: At baseline and after 12 weeks of intervention

  10. Sleep Quality Index (PSQI)

    Changes in sleep quality according to the Pittsburgh Sleep Quality Index questionnaire on a scale from 1 (worst outcome) to 4 (best outcome). Higher scores indicate better sleep quality.

    Time frame: At baseline and after 12 weeks of intervention

  11. Adverse effects

    All categories of adverse effects as determined by structured monthly telephone interview

    Time frame: From baseline assessment to 12 week control assessment (during the intervention)

07

Study locations

2 sites
  • Faculty of Medicine, University of Tuebingen
    Erlangen, 91052, Germany
  • Institute of Radiology, University Hospital Erlangen
    Erlangen, 91054, Germany
08

References and documents

Publications

  • Kemmler W, Kohl M, von Stengel S, Willert S, Kast S, Uder M. Effects of whole-body electromyostimulation with different impulse intensity on blood pressure changes in hyper- and normotensive overweight people. A pilot study. Front Physiol. 2024 Feb 22;15:1349750. doi: 10.3389/fphys.2024.1349750. eCollection 2024. PubMed 38455842 ↗
  • Johnson JL, Slentz CA, Houmard JA, Samsa GP, Duscha BD, Aiken LB, McCartney JS, Tanner CJ, Kraus WE. Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise). Am J Cardiol. 2007 Dec 15;100(12):1759-66. doi: 10.1016/j.amjcard.2007.07.027. Epub 2007 Oct 29. PubMed 18082522 ↗
  • Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. PubMed 2748771 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 21 months is close to that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 12, 2026
StartActual
Feb 15, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Dec 31, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07406191
Collaborators
Universität Tübingen
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Feb 15, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 14, 2026

Study contacts

Wolfgang Kemmler, PhD
principal investigator · Institute of Radiology, University Hospital Erlangen, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion